Welcome to Markets Desk, here's what's moving the needle this afternoon.
A provocative warning out of MarketWatch today, where analysts are drawing uncomfortable parallels between the current IPO pipeline and the equity issuance records set in nineteen twenty nine and two thousand. The argument is pointed: if SpaceX and OpenAI come to market in size, the flood of new supply could overwhelm demand and trigger a correction as steep as forty percent.
Shifting to the AI arms race, the United States has moved to block foreign access to Anthropic's models, and the ripple effects are already reshaping global policy. Governments from Europe to Southeast Asia are accelerating sovereign AI strategies, pouring capital into domestic compute infrastructure rather than remain dependent on American platforms. The geopolitical dimension of artificial intelligence is no longer theoretical.
And in the biotech space, Insilico Medicine and South Korea's SK Biopharmaceuticals have announced a partnership valued at more than two point five billion dollars, targeting neuroimmune therapies. Insilico brings its Pharma dot AI platform to candidate design, while SK steers late-stage development and commercialization. It is one of the largest AI-driven drug discovery deals on record and signals deepening conviction in machine-led medicine.
That's the tape. Markets Desk, signing off the floor.
